The genetic hallmark of FL is the chromosomal translocation t(14;18)(q32;q21) that leads to deregulated expression of the anti-apoptotic BCL2 proto-oncogene in the tumor cells thus allowing for the acquisition of secondary chromosomal alterations in the germinal center environment where the vast majority of non-neoplastic B-cells are physiologically destined to undergo apoptosis. 7 However, the translocation t(14;18) is not present in all FL cases, [8] [9] [10] and even with a highly sensitive fluorescence in situ hybridization (FISH) approach, rearrangements of BCL2 can only be detected in up to 90% of FL. 11 In contrast to FL carrying the t(14;18), FL lacking a BCL2 rearrangement are less well characterized and their pathogenesis remains largely unclear. A subset of t(14;18)-negative FL appears to harbor genetic rearrangements of the BCL6 gene in 3q27 10, 12, 13 or trisomy 3, 14 while others show BCL2 expression on the immunohistochemical level despite the lack of the t(14;18). 10 Moreover, increased expression of IRF4/MUM1, a protein associated with plasma
For personal use only. on June 12, 2017 . by guest www.bloodjournal.org From cell differentiation, 15 has been described in FL without BCL2 rearrangement. 14, 16 Cases of FL grade 3B, that may be biologically distinct from typical nodal FL grade 1-3A, 4, 17 were included in previous studies and may have confounded the reported results. This investigation, therefore, focuses on the clinical, genetic and molecular characterization of t(14;18)-negative FL within the spectrum of grades 1-3A. In a series of 184 well characterized FL grades 1-3A that underwent gene expression profiling by the Leukemia and Lymphoma Molecular Profiling Project (LLMPP) in a previous study, 6 we wished to determine the frequency of FL without BCL2 
Material and Methods

Follicular lymphoma specimens
Frozen as well as formalin fixed and paraffin embedded (FFPE) tumor tissues of 184 FL cases from our previous gene expression profiling study 6 were available for the current investigation. These included 152 FL grades 1/2 and 32 FL grade 3A. As a validation set, 84 FL cases (80 FL grades 1/2, four FL grade 3A) were selected from the files of the Institute of Pathology, University of Würzburg. All FL showed a predominantly follicular growth pattern and were classified according to the WHO criteria. 2 The entire study was approved by the Ethics Committee of the Medical Faculty, University of Würzburg.
Detection of BCL2 rearrangements
DNA extracted from frozen tissue of all 184 FL specimens was used in a polymerase chain reaction (PCR) to detect BCL2 rearrangements at both the major breakpoint region (MBR) and the minor cluster region (mcr) according to a standard protocol. Germany) using a cut-off of 8% for both the BCL2 and BCL6 break-apart probes as determined by FISH experiments in reactive tissues.
Comparative genomic hybridization (CGH) analysis
Conventional CGH was performed according to a standard protocol 19 in 184 FL with DNA extracted from the same frozen tissue specimens that were used for previous gene expression profiling experiments. 6 For graphical representation we used the imaging tools provided by the SKY/M-FISH and CGH database from which complete CGH data are available (http://www.ncbi.nlm.nih.gov/sky/).
Immunohistochemistry (IHC)
Immunostaining was performed on FFPE tissues according to standard protocols. 
Clonality (Genescan) analysis and analysis of ongoing SHM
Genescan analysis and analysis of ongoing somatic hypermutation was performed on selected FL cases (for details see supplementary information).
Results
Study cohorts
The previously published gene expression data set of 184 FL 6 
Chromosomal alterations in FL detected by CGH
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Chromosomal gains were frequently found in 1q, 2p, 7, 8q, 12q, 18q and X, whereas chromosomal losses occurred most frequently in 6q, 10q and 13q. These results are well in line with published reports. 8, 9 When correlating the presence of minimally altered chromosomal regions (MCR) with overall survival of FL patients, the presence of 18q21 amplifications correlated with inferior outcome. Only four tumors, however, carried this alteration, but all four patients died in less than five years (P=0.002).
Correlation of genetic alterations with gene expression
The analysis of associations between distinct chromosomal alterations and the expression levels of genes localized in each of these regions (Supplementary Table   1 ) revealed a total of 2465 probe sets that were significantly altered in gene expression, according to the t-test and a local FDR of <0.01 (Supplementary Table   2 ). Of those, more than 900 probe sets were significantly expressed at P-values <0.0001 when a Bonferroni correction was applied. With few exceptions, chromosomal gains were associated with increased expression and chromosomal losses were associated with decreased expression of genes localized in these regions. The probe sets revealed by the t-test approach could be assigned to 195 altered chromosomal bands, 41 of which showed a significant excess of association according to a Poisson model (Supplementary Table 3 ). Genes that showed significantly altered gene expression levels were assigned to the gene families 'oncogenes', 'tumor suppressor genes', 'transcription factors', 'translocated genes', 'cytokines' and 'kinases'. Some of these annotated genes in the chromosomal regions 1q, 2p, 6q, 7q, 8q, 10q, 12q and 18q are displayed in Figure 1B (for complete data see supplementary Table 4A and B and supplementary Figure 1 A-M). Notably, we obtained similar results using GSEA thus validating the findings by a different mathematical approach (data not shown). Next, we analyzed whether the presence of any of the MCRs was associated with the expression level of the two prognostically relevant bystander signatures in FL, the immune response 1 (IR1) and immune response 2 (IR2) signatures. 6 Interestingly, each MCR was associated with a decreased expression signature of IR1 with almost half of these associations having a P-value of less than 0.05, whereas no statistical correlations could be detected between the gene expression level of IR2 and any of the MCRs. 
Definition of FL subgroups according to the presence of the t(14;18) and BCL2 protein expression
As detailed above, of 164 FL with available information 147 cases carried the t(14;18), whereas it was lacking in 17 cases. Among the 17 t(14;18)-negative FL, eleven cases were negative for BCL2 expression on the immunohistochemical level, whereas six cases were positive (Figure 2 ). The incidence of the t(14;18) did not differ between the FL grades 1/2 and 3A (90% vs. 86%, respectively).
Clonal IgV H rearrangements and ongoing SHM were detected in all cases tested (supplementary information).
FL with and without t(14;18) differ in the presence of 18q11-q21 gains/amplifications
By CGH analysis, various genetic alterations were present at different frequencies between t(14;18)-positive and t(14;18)-negative FL. Gains in chromosome 7 (19.5%), 8q (16%), X (13.5%) and losses in 13q (14%) and 10q (12.5%) were only encountered in t(14;18)-positive FL ( Figure 3A and B 
High density SNP array analysis of t(14;18)-negative FL
To define chromosomal gains and losses of t(14;18)-negative FL at higher resolution, we studied eleven cases by SNP arrays. The results that are summarized in Figure 4 confirmed the alterations previously identified by CGH with only few minor exceptions, but also revealed additional alterations. Strikingly, four t(14;18)-negative FL (36%) carried small gains or amplifications in the chromosomal region 2p16
including the BCL11A and REL loci that were not evident in the conventional CGH Figure 4) ; interestingly, this gain did not include the BCL2 locus. However, no alterations that were specific for the t(14;18)-negative FL subgroup could be detected using this high resolution approach.
FL with and without t(14;18) differ in gene expression profiles
The comparison of gene expression profiles between FL with and without t (14;18) revealed 1562 differentially expressed probe sets between the two groups using a two-sided t-test (P<0.001). As expected, BCL2 was the most differentially expressed gene (P-value<0.0001), with a higher expression in t(14;18)-positive cases.
Subsequent GSEA analysis displayed major differences between the two groups. In Table 6 ).
Finally, we also compared gene expression profiles between 147 FL carrying the t(14;18) and six FL that were t(14;18)-negative, but showed BCL2 expression by immunohistochemistry. Interestingly, GCB-associated signatures remained enriched among t(14;18)-positive FL, whereas ABC-, NFκB-and proliferation-associated signatures were enriched with FL lacking the t(14;18). This result suggests that the expression of BCL2 in t(14;18)-negative FL may not be sufficient to alter the gene expression phenotype towards the profile of t(14;18)-positive FL (data not shown).
Differences in clinical parameters between FL with and without t(14;18)
The Table 7 , supplementary Figure 2 ).
Immunohistochemical validation of gene expression data in an independent cohort of FL with and without t(14;18)
In an attempt to validate findings derived from the comparison of gene expression profiles between t(14; IHC results are summarized in Table 2 and examples of various stainings are provided in Figure 5 . Striking differences were observed for CD10; while all FL with the t(14;18) were strongly positive for this marker, CD10 expression was lacking or only weakly present in 32% of FL without t(14;18) which is in line with the gene expression profiling results that demonstrated an enrichment of GCB-associated genes in FL with t(14;18). Interestingly, low or absent CD10 expression was The data discussed in this study has been deposited in NCBI's Gene Expression Omnibus and are accessible through GEO Series accession number GSE16131. Our CGH analysis in the whole series of 184 FL identified recurrent gains in the chromosomal regions 1q, 2p, 12q, 18q as well as losses in 6q, 10q and 13q at similar frequencies as previously reported 9, 24 indicating that the present series includes a representative spectrum of genetic alterations typically observed in FL. We specifically excluded FL grade 3B cases from our investigation based on the accumulating evidence that these tumors may be molecularly distinct from FL grades 1-3A. 4, 25 When comparing the genetic alterations in the t(14;18)-positive and t(14;18)-negative FL subsets, 18q gains or amplifications were surprisingly restricted to the t(14;18)-positive FL subset. This result is in contrast to a previous study in which gains in 18q
Discussion
were frequently observed in t(14;18)-negative FL. 10 It is unlikely that this discrepancy contrast to a recent study by Nanjangud and colleagues. 29 Again, that study included FL grade 3B cases that frequently lack the t(14;18) and show a high karyotypic complexity. This difference is statistically highly significant (P<0.01), and it is important to point out that the distribution of the FL grades 1/2 and 3A was equal between the groups.
More precisely, our validation set contained only four FL grade 3A two of which carried the t(14;18). Considering the known correlation between increased Ki67 labeling and a higher grade of FL cases, a bias in the composition of the two FL subgroups in our validation cannot account for the observed differences in the proliferation rate. We therefore conclude that an increased proliferative activity is an inherent biological feature of t(14;18)-negative FL. Since FL grade 3B cases had been excluded from our study and since only few cases showed expression of IRF4/MUM1, we did not observe a significant association between increased Ki67 staining and a higher level of IRF4/MUM1 expression, as reported previously. 30 Gene expression signatures also point to an increased level of NFκB activity within the subset of t(14;18)-negative FL, as evidenced by increased expression levels of well known NFκB target genes. In addition, the composition of the microenvironment, an important biologic and prognostic feature in FL, 6 appears to differ between the subgroups, as evidenced by an enrichment of the IR1 and T-cell signatures in It is important to note that FL subsets that frequently lack the t(14;18) and show distinct genetic and clinical features were not included in the present study.
Specifically, pediatric follicular lymphomas, cutaneous follicle center lymphomas and the recently described FL subgroup with a predominantly diffuse growth pattern and frequent deletions in the chromosomal region 1p36 33 were excluded from our investigation, for which only FL with a predominantly follicular growth pattern were selected.
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